ClinicalTrials.gov
public full text
Public Domain
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
RATIONALE: Vaccines made from gp100 and sargramostim may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy with gp100 and/or sargramostim in treating patients who have malignant melanoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma#840430
- Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma#892512
- Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma#287394
- Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma#845108
- Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma#444755
Record · ID 1375784
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive